Lili Yuen1, Pouya Saeedi2, Musarrat Riaz3, Suvi Karuranga2, Hema Divakar4, Naomi Levitt5, Xilin Yang6, David Simmons7. 1. International Diabetes Federation Atlas 9th Edition Hyperglycaemia in Pregnancy Special Interest Group (HIP-SIG), Belgium; School of Medicine, Western Sydney University, Campbelltown, Australia. 2. International Diabetes Federation Atlas 9th Edition Hyperglycaemia in Pregnancy Special Interest Group (HIP-SIG), Belgium; International Diabetes Federation, Brussels, Belgium. 3. International Diabetes Federation Atlas 9th Edition Hyperglycaemia in Pregnancy Special Interest Group (HIP-SIG), Belgium; Baqai Medical University, Karachi, Pakistan. 4. International Diabetes Federation Atlas 9th Edition Hyperglycaemia in Pregnancy Special Interest Group (HIP-SIG), Belgium; Divakar's Specialty Hospital, Bengaluru, India; Federation of Obstetric and Gynaecological Societies of India (FOGSI), India. 5. International Diabetes Federation Atlas 9th Edition Hyperglycaemia in Pregnancy Special Interest Group (HIP-SIG), Belgium; University of Cape Town, South Africa. 6. International Diabetes Federation Atlas 9th Edition Hyperglycaemia in Pregnancy Special Interest Group (HIP-SIG), Belgium; Tianjin Medical University, Tianjin, China. 7. International Diabetes Federation Atlas 9th Edition Hyperglycaemia in Pregnancy Special Interest Group (HIP-SIG), Belgium; School of Medicine, Western Sydney University, Campbelltown, Australia. Electronic address: Da.Simmons@westernsydney.edu.au.
Abstract
AIM: Hyperglycaemia in pregnancy (HIP) is one of the most common complications of pregnancy. This study aims to examine the projected HIP prevalence in 2030 and 2045 using multiple methods. METHODS: The International Diabetes Federation Diabetes Atlas 2019 prevalence was projected to 2030 and 2045 by: (1) carrying forward the 2019 age-adjusted prevalence rates; (2) applying a linear regression of the past four editions of the IDF Diabetes Atlas; (3) applying a regression of the previous editions with the most consistent trend, followed by extrapolation from the 9th edition HIP estimate. RESULTS: Respectively, for 2030 and 2045, Method 1 projected a declining HIP rate with prevalences of 14.0% and 13.3%, Method 2 projected an increasing HIP prevalence at 16.5% and 18.3%, Method 3 predicted stabilisation of the rate from 16.0% to 15.8%. CONCLUSION: Assuming other factors remain unchanged, our best estimation of age-adjusted HIP will show stabilisation between 2019 and 2045 of 15.8% to 16.0%. However, this estimate is confounded by the heterogeneity of studies and the influence of different gestational diabetes mellitus diagnostic criteria. To provide accurate future comparisons we recommend standardising the diagnostic criteria to the International Association of Diabetes in Pregnancy Study Groups.
AIM: Hyperglycaemia in pregnancy (HIP) is one of the most common complications of pregnancy. This study aims to examine the projected HIP prevalence in 2030 and 2045 using multiple methods. METHODS: The International Diabetes Federation Diabetes Atlas 2019 prevalence was projected to 2030 and 2045 by: (1) carrying forward the 2019 age-adjusted prevalence rates; (2) applying a linear regression of the past four editions of the IDF Diabetes Atlas; (3) applying a regression of the previous editions with the most consistent trend, followed by extrapolation from the 9th edition HIP estimate. RESULTS: Respectively, for 2030 and 2045, Method 1 projected a declining HIP rate with prevalences of 14.0% and 13.3%, Method 2 projected an increasing HIP prevalence at 16.5% and 18.3%, Method 3 predicted stabilisation of the rate from 16.0% to 15.8%. CONCLUSION: Assuming other factors remain unchanged, our best estimation of age-adjusted HIP will show stabilisation between 2019 and 2045 of 15.8% to 16.0%. However, this estimate is confounded by the heterogeneity of studies and the influence of different gestational diabetes mellitus diagnostic criteria. To provide accurate future comparisons we recommend standardising the diagnostic criteria to the International Association of Diabetes in Pregnancy Study Groups.
Authors: Temitope C Ekundayo; Ayodeji O Falade; Bright E Igere; Chidozie D Iwu; Mary A Adewoyin; Tosin A Olasehinde; Oluwatosin A Ijabadeniyi Journal: Sci Rep Date: 2022-03-17 Impact factor: 4.379
Authors: Vesna D Garovic; Ralf Dechend; Thomas Easterling; S Ananth Karumanchi; Suzanne McMurtry Baird; Laura A Magee; Sarosh Rana; Jane V Vermunt; Phyllis August Journal: Hypertension Date: 2021-12-15 Impact factor: 9.897
Authors: Garima Meena; Jayaseelan Venkatachalam; Palanivel Chinnakali; Jeby J Olickal; Karthiga V Kumar; Sadhana Subramanian; Papa Dasari Journal: J Family Med Prim Care Date: 2021-01-30